Drug Profile
Research programme: Alzheimer's disease diagnostics - GE Healthcare/Janssed Pharmaceutica
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GE Healthcare; Janssen Pharmaceutica
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease(Diagnosis) in USA
- 02 Dec 2010 Early research in Alzheimer's disease diagnosis in USA (unspecified route)